Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

NCT02855684 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

604

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine (U300)
DRUG: Insulin glargine
DRUG: Non-insulin antihyperglycemic drugs

Sponsor

Sanofi